Key Highlights
● Third-quarter net Revenue reached a record $37.6 million, up 3.0%.
● Pro-forma growth was 10.2%, adjusting for the restructuring of a biomedical services arrangement.
● Adjusted EBITDA increased 12.5% to $9.4 million, a 24.9% margin.
● Patient Services revenue climbed 15.4% to $25.8 million.
InfuSystem Holdings, Inc. (NYSE American:INFU) enters the final weeks of 2026 with its full-year targets intact. In third-quarter results released Nov. 5, the provider of infusion pumps and related services reaffirmed guidance for pro-forma revenue growth of 6% to 8% and an adjusted EBITDA Margin in the low-to-mid 20% range. With nine months of results now reported, that reaffirmation sets up the fourth quarter as the period that determines whether the company lands inside its own range, making the implied year-end math a practical focus for investors following the stock.
Latest Company Context
Third-quarter net revenue reached a record $37.6 million, up 3.0% from $36.5 million a year earlier, according to the company's Earnings release filed with the SEC. On a pro-forma basis, adjusting for the restructuring of its GE Healthcare (NASDAQ:GEHC) biomedical services arrangement, growth was 10.2%. That restructuring reduced third-quarter revenue by about $2.4 million, and Device Solutions revenue fell 16.6% to $11.8 million as a result. Patient Services revenue climbed 15.4% to $25.8 million, helped by 7.2% oncology growth and a 112% jump in wound care. Net Income rose to $3.2 million, or $0.15 per diluted share, from $2.3 million, or $0.11. Adjusted EBITDA increased 12.5% to $9.4 million, lifting the margin to 24.9% from 22.8%. Nine-month revenue totaled $108.2 million, up 0.9% on a reported basis. Gross margin improved to 57.8% from 57.1%.
Key Business and index Drivers
The gap between reported and pro-forma growth is central to reading the guidance. Because the GE Healthcare change removes revenue that carried lower strategic value, management frames performance on a pro-forma basis, and the reaffirmed 6% to 8% range applies to that measure rather than reported revenue. Patient Services, which posted a 61.5% gross margin in the quarter versus 49.7% for Device Solutions, is the main engine; continued expansion in oncology and wound care could support the upper half of the range.
Profitability guidance also appears to have some cushion: the third-quarter adjusted EBITDA margin of 24.9% sat at or above the top of the low-to-mid 20% target. Balance-sheet capacity adds flexibility. Net Debt was $10.6 million, equal to 0.32 times trailing adjusted EBITDA, and total Liquidity was $64.1 million, including $55.0 million of revolver availability. The company also repurchased about $5.0 million of stock in the first nine months.
What Investors Should Watch
Several items may shape fourth-quarter interpretation. First, the pace of wound care growth, which more than doubled year over year in the third quarter, could indicate whether that line can keep contributing meaningfully. Second, the Working Capital effects of the ERP system that went live March 1, 2026, remain relevant: the company estimated about $5.0 million of temporary pressure in the third quarter, with roughly $1.3 million converted to cash by October. Further collections could affect year-end cash and leverage. Third, investors may watch whether repurchases continue at a similar pace. The company noted that the third-quarter figures remain preliminary until its 10-Q is filed, and full-year 2026 results would typically follow in the first quarter of 2027. A replay of the Nov. 10 conference call is available through Feb. 10, 2027.
A Fourth-Quarter Test of Reaffirmed Targets
InfuSystem's reaffirmed outlook frames the fourth quarter as a test of whether pro-forma growth and margin gains in Patient Services can offset the revenue removed by the GE Healthcare restructuring. Third-quarter margins were at or above the target range and Leverage remained low, while ERP-related collections and the durability of wound care growth are open questions. How those factors resolve could determine where the company finishes within its guidance when it reports full-year results. Leverage and liquidity also leave room for management to continue Buybacks while funding growth initiatives.






Please wait processing your request...